Clinical Trials
5 trialsNCT04806035 2024-07-31
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
Phase 1 Terminated
NCT03804996 2024-04-08
Study of TG-1801 in Subjects With B-Cell Lymphoma
TG Therapeutics, Inc.
Phase 1 Completed
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02276963 2019-06-06
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Phase 1 Completed
NCT01098188 2012-04-30
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Laboratoire français de Fractionnement et de Biotechnologies
Phase 1 Completed